Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
- Resource Type
- article
- Authors
- Christie M. Ballantyne; Mehar S. Manku; Harold E. Bays; Sephy Philip; Craig Granowitz; Ralph T. Doyle; Rebecca A. Juliano
- Source
- Cardiology and Therapy, Vol 8, Iss 1, Pp 79-90 (2019)
- Subject
- Arachidonic acid
Eicosapentaenoic acid
Fatty acids
Hypertriglyceridemia
Icosapent ethyl
Omega-3 fatty acids
Diseases of the circulatory (Cardiovascular) system
RC666-701
- Language
- English
- ISSN
- 2193-8261
2193-6544
Abstract Introduction Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia. Methods This was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200–499 mg/dl and controlled low-density lipoprotein cholesterol (40–99 mg/dl). This analysis examined effects of icosapent ethyl 4 g/day versus placebo on fatty acid levels in plasma and RBCs using a gas chromatograph assay method with flame ionization detector. Results In plasma, treatment with icosapent ethyl 4 g/day resulted in significant increases versus placebo in the mean concentrations of EPA (+ 635%; P